Biocytogen’s In Vivo Drug Screening Platform Accelerated 4-1BB Agonistic Antibody Development

Biocytogen’s In Vivo Drug Screening Platform Accelerated 4-1BB Agonistic Antibody Development

Author: Benny Yang, Jian Ni, Yuelei Shen, Qingcong Lin

AACR Annual Meeting 2019 # 23794-1BB (TNFRSF9/CD137) belongs to the TNFR superfamily. 4-1BB is expressed by activated CD4 helper T cells, B cells, natural killer cells, natural killer T cells, dendritic cells, and activated endothelium. 4-1BB enhances tumor rejection by upregulating on T cells following activation and its engagement increases T cell proliferation and proinflammatory cytokine production. Fortunately, new therapeutic modalities using 4-1BB targeting aptamers as well as therapeutic combinations with other immuno-modulatory and traditional anti-cancer treatments have revived excitement for the use of 4-1BB agonists in the clinic.

We are interested in discovering novel 4-1BB therapeutic antibodies for cancer patients. Candidate molecules obtained through the classical hybridoma technology were screened by high-throughput flow cytometry. Then, we took the advantages of Biocytogen’s humanized mice and screened the purified antibodies in B-h4-1BB mice bearing MC-38 tumor cells. We found some antibodies that worked as equivalent as BMS’s Urelumab. To determine which isotype should be adopted, we engrafted the antigen binding domain onto various human Fc backbones. Interestingly, we found that the human IgG1 isotype appeared more effective against tumor than other isotypes in B-4-1BB mice baring MC-38 tumors. This study provides a reliable basis for our follow-up mechanism research and clinical evaluation on this target.

Share:

Please fill out the form below to request a download of this poster